Edition:
United Kingdom

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

3.60USD
24 Apr 2018
Change (% chg)

$0.02 (+0.56%)
Prev Close
$3.58
Open
$3.57
Day's High
$3.69
Day's Low
$3.51
Volume
279,015
Avg. Vol
363,858
52-wk High
$6.19
52-wk Low
$3.24

Chart for

About

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast... (more)

Overall

Beta: 2.17
Market Cap(Mil.): $409.77
Shares Outstanding(Mil.): 87.00
Dividend: --
Yield (%): --

Financials

  AGEN.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.27 -- --
ROI: -75.39 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-Agenus Reports Q4 Loss Per Share $0.35

* AGENUS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

15 Mar 2018

BRIEF-Agenus Inc Files For Sale Of Up 10 Mln Shares Of Common Stock By Selling Stockholders

* AGENUS INC FILES FOR SALE OF UP 10 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text (http://bit.ly/2n84why) Further company coverage:

24 Jan 2018

BRIEF-Agenus Announces Combination Clinical Trials Of Anti-CTLA4 & Anti-PD1

* AGENUS ANNOUNCES COMBINATION CLINICAL TRIALS OF ITS ANTI-CTLA4 (AGEN1884) & ANTI-PD1 (AGEN2034)

22 Jan 2018

BRIEF-Agenus Announces $230 Mln Royalty Monetization With Healthcare Royalty Partners

* AGENUS INC. ANNOUNCES $230 MILLION ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS

08 Jan 2018

BRIEF-Agenus reports Q3 loss per share $0.37

* Agenus reports third quarter 2017 financial results and provides corporate update

07 Nov 2017

Earnings vs. Estimates